logo
Share SHARE
FONT-SIZE Plus   Neg

Beware Of Tainted Weight Loss Pills, Warns FDA

yellowpills-040612.jpg

Consumers are advised not to purchase or use "Japan Rapid Weight Loss Diet Pills", a product for weight loss, as they contain a cancer-causing agent, warns the FDA.

The "Japan Rapid Weight Loss Pills", which are available in three different colors namely, green, yellow and blue, are sold on various websites, such as www.ebay.com, and distributed by a company called Xiushentang.

A laboratory analysis by the FDA has confirmed that these weight loss diet pills contain undeclared Phenolphthalein and Sibutramine.

Phenolphthalein is a chemical capable of potentially damaging or even causing mutations in a person's DNA. The FDA has classified Phenolphthalein as "not generally recognized as safe and effective."

Sibutramine is a substance known to substantially increase blood pressure and/or pulse rate in some patients.

Remember, Abbott Laboratories' obesity drug Meridia, which was pulled off the market in October 2010 due to increased risk of heart attack and stroke? The active ingredient in Meridia was also Sibutramine.

The FDA in a statement said that consumers should stop using these products immediately and throw them away. Consumers who have experienced any negative side effects should consult a health care professional as soon as possible.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
French real estate company Unibail-Rodamco SE Tuesday announced that it has entered into an agreement to acquire Australian shopping centre group Westfield Corp. in a deal that implies an enterprise value of $24.7 billion. The deal is expected to create the world's premier developer and operator of flagship shopping destinations with 61.1 billion euros or $72.2 billion of Gross Market Value. Aerospace and defense major Boeing's shares increased in the extended trading on Monday after the company announced a 20 percent increase in quarterly dividend and also boosted its share repurchase program to $18 billion, citing its strong and growing cash flow. Checkout the companies that are expected to release quarterly financial results on Tuesday, December 12, 2017. * ARWR to benefit from collaboration agreement with Amgen * Demand for PoS software, PaaS technologies to propel PAY Q4
comments powered by Disqus
Follow RTT